Bile acid sequestrants: Risk– benefits and role in treating dyslipidemias

Om P. Ganda, Abhimanyu Garg

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Much progress has been made during the past two decades in the management of lipid disorders and consequent reduction in mortality from cardiovascular disease. However, many people remain inadequately treated and not at lipid goals. Bile acid sequestrants (BAS) have been an effective modality for treatment of hypercholesterolemia and elevated low-density lipoprotein-cholesterol (LDL-C) for more than 50 years. Well- designed angiographic and clinical trials have documented the successful reduction in atherosclerotic burden and cardiovascular events with the use of BAS in monotherapy and combination therapy with other lipid-lowering agents. Despite the availability of statins as the preferred agents for LDL-C lowering, BAS have proven to be of value as second-line therapy or as adjunct therapy when LDL-C goals are not achievable with statins alone. Due to a lack of systemic absorption, BAS have no major adverse effect. The newer BAS may be associated with better tolerability and side effects. In patients with type 2 diabetes, or those at a risk of diabetes, BAS have a unique advantage of a dual effect, namely reduction in LDL-C and a modest but significant effect on reducing hyperglycemia. The precise mechanism of the glucose-lowering effect is not fully understood.

Original languageEnglish (US)
Title of host publicationDyslipidemias: Pathophysiology, Evaluation and Management
PublisherHumana Press Inc.
Pages453-463
Number of pages11
ISBN (Print)9781607614241, 9781607614234
DOIs
StatePublished - Jan 1 2015

Fingerprint

Dyslipidemias
Bile Acids and Salts
LDL Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Therapeutics
Hypercholesterolemia
Hyperglycemia
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Clinical Trials
Glucose
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ganda, O. P., & Garg, A. (2015). Bile acid sequestrants: Risk– benefits and role in treating dyslipidemias. In Dyslipidemias: Pathophysiology, Evaluation and Management (pp. 453-463). Humana Press Inc.. https://doi.org/10.1007/978-1-60761-424-1_27

Bile acid sequestrants : Risk– benefits and role in treating dyslipidemias. / Ganda, Om P.; Garg, Abhimanyu.

Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., 2015. p. 453-463.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ganda, OP & Garg, A 2015, Bile acid sequestrants: Risk– benefits and role in treating dyslipidemias. in Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., pp. 453-463. https://doi.org/10.1007/978-1-60761-424-1_27
Ganda OP, Garg A. Bile acid sequestrants: Risk– benefits and role in treating dyslipidemias. In Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc. 2015. p. 453-463 https://doi.org/10.1007/978-1-60761-424-1_27
Ganda, Om P. ; Garg, Abhimanyu. / Bile acid sequestrants : Risk– benefits and role in treating dyslipidemias. Dyslipidemias: Pathophysiology, Evaluation and Management. Humana Press Inc., 2015. pp. 453-463
@inbook{1985890a610745e1aba123a2a4901359,
title = "Bile acid sequestrants: Risk– benefits and role in treating dyslipidemias",
abstract = "Much progress has been made during the past two decades in the management of lipid disorders and consequent reduction in mortality from cardiovascular disease. However, many people remain inadequately treated and not at lipid goals. Bile acid sequestrants (BAS) have been an effective modality for treatment of hypercholesterolemia and elevated low-density lipoprotein-cholesterol (LDL-C) for more than 50 years. Well- designed angiographic and clinical trials have documented the successful reduction in atherosclerotic burden and cardiovascular events with the use of BAS in monotherapy and combination therapy with other lipid-lowering agents. Despite the availability of statins as the preferred agents for LDL-C lowering, BAS have proven to be of value as second-line therapy or as adjunct therapy when LDL-C goals are not achievable with statins alone. Due to a lack of systemic absorption, BAS have no major adverse effect. The newer BAS may be associated with better tolerability and side effects. In patients with type 2 diabetes, or those at a risk of diabetes, BAS have a unique advantage of a dual effect, namely reduction in LDL-C and a modest but significant effect on reducing hyperglycemia. The precise mechanism of the glucose-lowering effect is not fully understood.",
author = "Ganda, {Om P.} and Abhimanyu Garg",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-60761-424-1_27",
language = "English (US)",
isbn = "9781607614241",
pages = "453--463",
booktitle = "Dyslipidemias: Pathophysiology, Evaluation and Management",
publisher = "Humana Press Inc.",

}

TY - CHAP

T1 - Bile acid sequestrants

T2 - Risk– benefits and role in treating dyslipidemias

AU - Ganda, Om P.

AU - Garg, Abhimanyu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Much progress has been made during the past two decades in the management of lipid disorders and consequent reduction in mortality from cardiovascular disease. However, many people remain inadequately treated and not at lipid goals. Bile acid sequestrants (BAS) have been an effective modality for treatment of hypercholesterolemia and elevated low-density lipoprotein-cholesterol (LDL-C) for more than 50 years. Well- designed angiographic and clinical trials have documented the successful reduction in atherosclerotic burden and cardiovascular events with the use of BAS in monotherapy and combination therapy with other lipid-lowering agents. Despite the availability of statins as the preferred agents for LDL-C lowering, BAS have proven to be of value as second-line therapy or as adjunct therapy when LDL-C goals are not achievable with statins alone. Due to a lack of systemic absorption, BAS have no major adverse effect. The newer BAS may be associated with better tolerability and side effects. In patients with type 2 diabetes, or those at a risk of diabetes, BAS have a unique advantage of a dual effect, namely reduction in LDL-C and a modest but significant effect on reducing hyperglycemia. The precise mechanism of the glucose-lowering effect is not fully understood.

AB - Much progress has been made during the past two decades in the management of lipid disorders and consequent reduction in mortality from cardiovascular disease. However, many people remain inadequately treated and not at lipid goals. Bile acid sequestrants (BAS) have been an effective modality for treatment of hypercholesterolemia and elevated low-density lipoprotein-cholesterol (LDL-C) for more than 50 years. Well- designed angiographic and clinical trials have documented the successful reduction in atherosclerotic burden and cardiovascular events with the use of BAS in monotherapy and combination therapy with other lipid-lowering agents. Despite the availability of statins as the preferred agents for LDL-C lowering, BAS have proven to be of value as second-line therapy or as adjunct therapy when LDL-C goals are not achievable with statins alone. Due to a lack of systemic absorption, BAS have no major adverse effect. The newer BAS may be associated with better tolerability and side effects. In patients with type 2 diabetes, or those at a risk of diabetes, BAS have a unique advantage of a dual effect, namely reduction in LDL-C and a modest but significant effect on reducing hyperglycemia. The precise mechanism of the glucose-lowering effect is not fully understood.

UR - http://www.scopus.com/inward/record.url?scp=84956820112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956820112&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-424-1_27

DO - 10.1007/978-1-60761-424-1_27

M3 - Chapter

AN - SCOPUS:84956820112

SN - 9781607614241

SN - 9781607614234

SP - 453

EP - 463

BT - Dyslipidemias: Pathophysiology, Evaluation and Management

PB - Humana Press Inc.

ER -